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Abstract
Background: We investigated the role of infection with genital and cutaneous human
papillomavirus types (HPV) in the aetiology of ocular surface squamous neoplasia (which includes
both conjunctival intraepithelial neoplasia (CIN) and carcinoma) using data and biological material
collected as part of a case-control study in Uganda.
Results: Among 81 cases, the prevalence of genital and cutaneous HPV types in tumour tissue did
not differ significantly by histological grade of the lesion. The prevalence of genital HPV types did
not differ significantly between cases and controls (both 38%; Odds ratio [OR] 1.0, 95% confidence
interval [CI] 0.4–2.7, p = 1.0). The prevalence of cutaneous HPV types was 22% (18/81) among
cases and 3% (1/29) among controls (OR 8.0, 95% CI 1.0–169, p = 0.04).
Conclusion: We find no evidence of an association between genital HPV types and ocular surface
squamous neoplasia. The prevalence of cutaneous HPV was significantly higher among cases as
compared to controls. Although consistent with results from two other case-control studies, the
relatively low prevalence of cutaneous HPV types among cases (which does not differ by
histological grade of tumour) indicates that there remains considerable uncertainty about a role for
cutaneous HPV in the aetiology of this tumour.
Background
In the years before the HIV epidemic, corneo-conjunctival
intraepithelial neoplasia (CIN) and carcinoma (together
called ocular surface squamous neoplasia (OSSN)) were
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reported to be more frequent in African countries than in
Europe and the USA [1-3]. Using data from worldwide
cancer registries it has been confirmed that incidence of
OSSN increases markedly with proximity to the equator,
presumably from increasing solar ultraviolet (UV) radia-
tion [3]. Exposure to UV radiation is an established cause
of disease. Lesions occur in sun-exposed areas of the eye
[4,5], are associated with solar elastosis [4-7] and have
been shown to contain classical UV-induced p53 muta-
tions [8]. The incidence of the tumour increases with
increasing levels of ambient solar radiation and associa-
tions with sun exposure and past history of skin cancer
have been identified in case-control studies [3,9-11].
Additional risk factors may also be important. For exam-
ple, a polymorphism of TP53 codon 72 has been linked to
an increased risk of neoplasia in one study from Uganda
including 107 cases and 115 controls [12]. Exposure to
dust and ocular trauma have also been suggested as possi-
ble risk factors, although evidence is scant [1,13].
Since the 1980s there has been a marked increase in cases
of conjunctival neoplasia, mostly in sub-Saharan Africa
[14-19]. In Uganda for example, the reported incidence
has more than tripled over the last decade [14,16], partic-
ularly among younger people and a link with HIV infec-
tion was suggested in case reports [20-27]. Case-control
studies in several African countries [11,28-33] and cohort
studies in the USA [34,35], have confirmed a roughly 10
fold excess risk of the tumour in HIV infected people com-
pared to the uninfected; in Africa the majority of cases are
HIV infected [36]. In a recent study of 414 cases in
Uganda, 64% of people with conjunctival neoplasia were
HIV infected and this applied to intraepithelial as well as
to invasive cases [5]. The median CD4+ T lymphocyte
count of HIV positive cases at diagnosis has been found in
this study to be 111 cells/microL (based on results from
112 HIV infected cases) [5]. Use of antiretroviral therapy
has been shown to cause tumour regression in an other-
wise inoperable case [37]. A recent report from the USA
did not find strong associations with level of immunosup-
pression in HIV infected people, but the study included
only 15 cases of the disease [35]. An excess risk has also
been reported among immunosuppressed cancer patients
and organ transplant recipients (although the number of
cases remains small) [38-42].
However, the clear excess risk of ocular surface epithelial
dysplasias among HIV infected people (and among
immunosuppressed renal transplant recipients) suggests a
role for an underlying infection in the aetiology [43,44].
Although an active search for other new oncogenic infec-
tions is ongoing, no new candidate virus (if one exists) has
yet been identified [45]. A causal relationship between
persistent infection with several (high risk) genital human
papillomavirus (HPV) types and cancer of the uterine cer-
vix is established. In non-melanoma skin carcinogenesis,
a role has been suggested for cutaneous HPV types from
the betapapillomavirus genus. A variety of HPV types has
already been identified in some, but not in all, tumour
specimens from several small case series and results from
case-control studies have, to date, been inconclusive [2].
Here we present results on the association of genital and
cutaneous (from the betapapillomavirus genus) HPV types
in relation to ocular surface epithelial neoplasias from a
case-control study in Uganda, together with a review of
published evidence.
Results
Paraffin-embedded biopsy material was available for 81
cases (mean age 35 years) and for 29 controls (mean age
30 years). Among cases, 17 people had lesions graded as
CIN (conjunctival intraepithelial neplasia) I, 18 were CIN
II, 22 were CIN III and 24 people had an invasive carci-
noma. Fifty two cases (64%) were HIV seropositive, 22
(27%) were seronegative and the HIV serostatus was
unknown for seven people (9%). Among controls, 15
people had pinguecula, 3 had chronic inflammation, two
had a pyogenic granuloma, two had a cavernous angioma
and seven had a variety of other diagnoses. Ten controls
(34%) were HIV seropositive and 19 (66%) were seroneg-
ative (Table 1). There were significantly more HIV serop-
ositive cases than controls (70% (52/74; seven cases had
unknown serostatus) versus 34%; p < 0.001).
Table 2 shows the prevalence of genital and cutaneous
HPV among controls, stratified by age, sex and HIV
serostatus – none of the apparent differences was statisti-
cally significant (at the 5% level). Table 3 shows the pro-
portion of cases with evidence of genital or cutaneous
HPV DNA in tumour tissue, stratified by the histological
grade of the lesion (CIN I – III and invasive carcinoma).
The prevalence of genital and cutaneous HPV types did
not differ significantly by histological grade of the lesion,
but at all grades, the prevalence of genital HPV types was
higher than that of cutaneous types. For all tumour grades
combined, this difference was statistically significant
(38% versus 22%; p = 0.03).
Overall, the prevalence of genital HPV types did not differ
between cases and controls (38% [31/81] in cases and
38% [11/29] among controls; OR 1.0, 95% CI 0.4–2.7, p
= 1.0). The genital HPV types identified were 6, 11, 16, 18,
31, 33, 35, 44, 51, 52, 66 and two that were unclassifiable.
High risk genital types were identified in 13 cases (types
16 [eight people], 51 and 66 [in one person], 18, 35, 51
and 52 [one person each]) and in three controls (types 31
and 33 [two people]). The most frequently detected geni-
tal type was HPV 11, which was found in 22 cases and in
10 controls. The prevalence of cutaneous HPV types was
22% (18/81) among cases and 3% (1/29) among controls
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(OR 8.0, 95%CI 1.0–168.5, p = 0.04) and did not differ
significantly between HIV infected and uninfected cases
and controls (Table 4). The cutaneous HPV types identi-
fied were 5, 8, 14, 17, 19, 23, 36, 37, 80, plus 9 that were
unclassifiable; HPV 14 was identified in three cases and
types 8, 17 and 23 were found in two people each. Evi-
dence of infection with more than one HPV type was iden-
tified in tissue from 19 cases and four controls.
Discussion
Our findings demonstrate that both genital and cutane-
ous HPVs can be found in conjunctival tissue – the genital
types were more frequently identified. However, we found
no evidence that genital types were associated with ocular
surface squamous neoplasia. In relation to cutaneous
HPV, results reported here are broadly consistent with
those from two other studies – the prevalence was signifi-
cantly higher among cases than among controls. How-
ever, the prevalence of cutaneous HPV was still relatively
low among cases and did not differ by histological grade
of the lesion.
A comprehensive review of the published literature iden-
tified 12 case reports or case series in which the prevalence
of HPV in tumour tissue from patients with ocular surface
squamous neoplasia was investigated [46-57]. Eleven
studies tested for HPV 16; seven also looked for evidence
of infection with HPV 18; four studies also included HPV
6 and/or 11, one looked at HPV 2 and in one study the
specific genital HPV type was not specified. Only three
studies included more than 20 cases, the largest having
38. The prevalence of detectable HPV varied from 0% to
93% (summarised in Table 5) – much of this variation
might be explained by the differing laboratory methodol-
ogies employed across individual studies. Sixteen case-
control studies were identified and are summarised in
Table 6, together with results from this investigation
[7,11,30,58-70]. With the exception of one study, in
which HPV type was not specified, all of the studies inves-
tigated HPV 16, nine also investigated HPV 18 and 5
investigated HPV 45. There is considerable heterogeneity
in results. For example, in relation to HPV 16, four studies
demonstrated a positive association and eleven showed
no association with ocular surface squamous neoplasia
Table 1: Distribution of cases and controls by age, sex and HIV serostatus
Percentage of cases (n) n = 81 Percentage of controls (n) n = 29
Age
15–28 27% (22) 38% (11)
29–32 27% (22) 31% (9)
33–70 46% (37) 31% (9)
Sex
Male 44% (36) 48% (14)
Female 56% (45) 52% (15)
HIV serostatus
Negative 27% (22) 66% (19)
Positive 64% (52) 34% (10)
Unknown 9% (7) 0% (0)
Table 2: The proportion of controls with evidence of infection 
with HPV, stratified by age, sex and HIV serostatus
All HPV Genital HPV Cutaneous-HPV
Age
15–28 27% (3/11) 27% (3/11) 9% (1/11)
29–32 33% (3/9) 33% (3/9) 0% (0/9)
33–70 56% (5/9) 56% (5/9) 0% (0/9)
Sex
Male 29% (4/14) 29% (4/14) 0% (0/14)
Female 47% (7/15) 47% (7/15) 7% (1/15)
HIV serostatus
Negative 32% (6/19) 32% (6/19) 0% (0/19)
Positive 50% (5/10) 50% (5/10) 10% (1/10)
TOTAL 38% (11/29) 38% (11/29) 3% (1/29)
None of the apparent differences in prevalence of HPV by age, sex or 
HIV sero-status was statistically significant.
Table 3: The proportion of cases with evidence of infection with 
HPV, stratified by histological grade of tumour
All HPV Genital HPV Cutaneous-HPV1
CIN I 47% (8/17) 35% (6/17) 29% (5/17)
CIN II 56% (10/18) 50% (9/18) 28% (5/18)
CIN III 45% (10/22) 27% (6/22) 23% (5/22)
Invasive 42% (10/24) 42% (10/24) 13% (3/24)
TOTAL 47% (38/81) 38% (31/81) 22% (18/81)
1. F2 (trend) = 1.9; p = 0.2
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(five studies failed to identify HPV 16 in either the cases
or controls). In most studies, type-specific methods of
HPV detection were used and so the types shown in the
tables were the only ones that were tested for.
Only three studies (including this one [68,69]) investi-
gated cutaneous HPV types – each demonstrated a signif-
icantly higher prevalence of cutaneous HPV in cases as
compared to controls (summarised in Table 7). Two of
the three studies examined the prevalence according to
histological grade of tumour (this study and reference 69)
and no association was demonstrated in either.
There is substantial variation in HPV prevalence rates
between different studies, which may have arisen, in part,
because of differences in patient selection, sample taking,
preparation and storage and detection method. Even for
PCR as a detection system, there are many variables that
influence the sensitivity and specificity and so could
impact on the reported prevalence. These include PCR
design (nested, broad spectrum or type-specific), the size
of the amplified product and the choice of the polymerase
used. This review was not done to draw attention to these
differences, but rather to show that there is no consistent
evidence for a causal association between HPV and OSSN.
In addition, however, it should be noted that the total
Table 4: The proportion of cases and controls with evidence of infection with HPV, stratified by HIV serostatus
All HPV1 Genital HPV2 Cutaneous-HPV3
Case4 Control Odds Ratio 
(95% CI)
Case4 Control Odds Ratio 
(95% CI)
Case4 Control Odds Ratio 
(95% CI)
HIV 
seronegativ
e
45% (10/22) 32% (6/19) 1.8 (0.4–7.9) 36% (8/22) 32% (6/19) 1.2 (0.3–5.5) 27% (6/22) 0% (0/19) f (1.8–f)
HIV 
seropositiv
e
48% (25/52) 50% (5/10) 0.9 (0.2–4.3) 40% (21/52) 50% (5/10) 0.8 (0.2–3.8) 21% (11/52) 10% (1/10) 2.2 (0.2–52)
TOTAL 47% (38/81) 38% (11/29) 1.5 (0.6–3.8) 38% (31/81) 38% (11/29) 1.0 (0.4–2.7) 22% (18/81) 3% (1/29) 8.0 (1.0–169)
1. More than one HPV type was identified in tissue from 19 cases and four controls
2. Genital HPV types investigated: 6, 11, 16, 18, 31, 33–35, 39, 40, 42–45, 51–54, 56, 58, 59, 66, 68, 70, 74. Genital HPV types identified: 6, 11, 16, 
18, 31, 33, 35, 44, 51, 52, 66, plus two unclassifiable; high risk genital types were identified in 13 cases (types 16 [eight people], 51 and 66 [in one 
person] 18, 35, 51 and 52 [one person each]) and in three controls (types 31 and 33 [two people]); HPV 11 was most frequently detected (22 cases 
and 10 controls)
3. Cutaneous HPV types investigated: 5, 8, 9, 12, 14, 15, 17, 19–25, 36–38, 47, 49, 75, 76, 80, 92, 93, 96. Cutaneous HPV types identified: 5, 8, 14, 
17, 19, 23, 36, 37, 80, plus 9 unclassifiable; HPV 14 was identified in three cases and types 8, 17 and 23 were found in two people each
4. Among cases, 7 had unknown HIV serostatus
Table 5: Summary of case series investigating the prevalence of HPV DNA in tumour tissue from patients with ocular surface 
squamous neoplasias.
Study [Reference] Detection method Number HPV positive/total (%) HPV type
McDonnell et al, 1987 [46] In situ hybridisation (ISH) 0/28 (0%) HPV 2, 6, 16, 18
McDonnell et al, 1989 [47] PCR 1/1 (100%) HPV 16
Lauer et al, 1990 [48] PCR 4/5 (80%) HPV 16
2/5 (40%) HPV18
Odrich et al, 1991 [49] PCR 2/2 (100%) HPV 16
McDonnell et al, 1992 [50] PCR 33/38 (87%) HPV 16
Tuppurainen et al, 1992 [51] ISH and PCR 0/4 (0%) HPV 6, 11, 16 and 18
Serna et al, 1995 [52] PCR 1/9 (11%) HPV 16
Nakamura et al, 1997 [53] ISH and PCR 2/8 (25%) HPV 16
2/8 (25%) HPV 18
Toth et al, 2000 [54] PCR 5/23 (9%) HPV types not specified
Eng et al, 2002 [55] PCR 0/20 (0%) HPV 6, 11, 16, 18
Moubayed et al, 2004 [56] ISH 12/14 (86%) HPV 16
13/14 (93%) HPV 18
12/14 (86%) HPV 6 and 11
Reszec and Sulkowski, 2005 [57] PCR 1/11 (9%) HPV 16
1/11 (9%) HPV 18
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number of cases and controls studied in this and in other
studies, remains relatively small.
Results reported here are also broadly similar to those
from case-control studies investigating the role of HPV in
the aetiology of cutaneous squamous cell carcinoma
(SCC) [71,72]. Moderate associations between cutaneous
HPV types and cutaneous SCC have been identified, but
doubt remains about whether this is causal. It has been
suggested that the increased serorecognition of HPV
among cases as compared to controls may arise as a result
of tumour formation [73]. Some support for this view
comes from a recent small prospective study, in which the
seroprevalence of antibodies against the L1 antigen of 38
HPV types among 39 cases of cutaneous squamous cell
carcinoma (SCC) for whom plasma was collected prior to
diagnosis (incident) and 80 controls was examined [72].
Fifteen cases having already developed SCC at blood col-
lection (prevalent) were also tested. There were no statis-
tically significant differences in the seroprevalence of
antibodies against any of the HPV types examined
between incident cases and controls, nor was there a dif-
ference in the seroprevalence of multiple infections. How-
ever, consistent with results from published case-control
studies, the seroprevalence against many cutaneous HPV
types was higher among prevalent cases than among
either incident cases or controls. This might suggest that if
HPV is involved in the aetiology of cutaneous squamous
Table 6: Summary of case-control studies investigating various HPV types in the aetiology of ocular surface squamous neoplasias
Study Detection method Number HPV positive/total (%) HPV type
Case Control
McDonnell et al, 1986 [58] In situ HPV antigen detection 5/61 (8%) 0/6 (0%) Unknown genital HPV type
McDonnell et al, 1989 [59] PCR 6/6 (100%) 0/6 (0%) HPV 16
Saegusa et al, 1995 [60] ISH and PCR 3/8 (38%) 0/12 (0%) HPV 16
Adachi et al, 1995 [61] PCR 1/5 (20%) 0/9 (0%) HPV 16
Waddell et al, 1996 [30] PCR 7/20 (35%) 2/15 (13%) HPV 16
Karcioglu and Issa, 1997 [62] PCR 4/45 (9%) 8/70 (11%) HPV 16
10/45 (22%) 10/70 (14%) HPV 18
Tabrizi et al, 1997 [63] PCR 20/88 (23%) 5/66 (8%) HPV 16 or 18
Dushku et al, 1999 [64] PCR 0/8 (0%) 0/16 (0%) L1 (all types)
Palazzi et al, 2000 [65] PCR 2/30 (7%) 1/30 (3%) HPV 16
Scott et al, 2002 [66] ISH and in situ reverse transcriptase PCR
5/10 (50%) 0/5 (0%) HPV 16
5/10 (50%) 0/5 (0%) HPV 18
Newton et al, 2002 [11] Serological analysis 8/39 (21%) 43/418 (10%) HPV 16
4/39 (10%) 16/418 (4%) HPV 18
2/39 (5%) 24/418 (6%) HPV 45
Tulvatana et al, 2003 [7] PCR 0/28 (0%) 0/23 (0%) Multiple types
Waddell et al, 2003 [67] Serological analysis 37/253 (15%) 6/37 (16) HPV 16
Ateenyi-Agaba et al, 2004 [68] PCR 0/21 (0%) 0/22 (0%) HPV 16, 18 and 45
0/22 (0%) 2/22 (9%) HPV 11
18/21 (86%) 7/20 (35%) Multiple cutaneous HPV types
Tornesello et al, 2006 [69] PCR 0/86 (0%) 1/63 (2%) HPV 6
2/86 (2%) 0/63 (0%) HPV 18
15/86 (17%) 0/63 (0%) Multiple cutaneous HPV types
Sen et al, 2007 [70] In situ HPV antigen detection 0/30 (0%) 0/30 (0%) Multiple genital HPV types
de Koning et al [this study] PCR 31/81 (38%) 11/29 (38%) Multiple genital HPV types
18/81 (22%) 1/29 (3%) Multiple cutaneous HPV types1
Table 7: Summary of case-control studies investigating cutaneous HPV types in the aetiology of ocular surface squamous neoplasias
Study [Reference] Prevalence of cutaneous HPV (number/total) Odds Ratio (95% Confidence Interval) and p value
Cases Controls
Ateenyi-Agaba et al, 2004 [68] 86% (18/21) 35% (7/20) 12.0 (1.7–84.9), p = 0.0021
Tornesello et al, 2006 [69] 17% (15/86) 0% (0/63) f (2.5–f), p = 0.0012
de Koning [this study] 22% (18/81) 3% (1/29) 8.0 (1.0–168.5), p = 0.04
1. For comparative purposes, the unadjusted odds ratio is shown
2. Estimated using Fisher exact test
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carcinoma, the process occurs close to the time of diagno-
sis, or that the antibody response observed in people with
the tumour is a consequence of tumour formation.
The possibility that the presence of a tumour facilitates
detection of antibodies against HPV is supported by the
findings of Favre et al (2000), who reported a higher sero-
prevalence of HPV-5 among patients with burns or with
proliferative cutaneous autoimmune diseases than among
controls [74]. Patients with psoriasis, involving abnormal
keratinocyte differentiation and proliferation, have also
shown a high HPV-5 seroprevalence [75]. This is thought
to arise as a consequence of cell proliferation in the skin
providing an environment that favours viral replication,
resulting in a rise in antibodies against the relevant HPV
type. Similarly, there is debate concerning the results
obtained from studies using tests for cutaneous HPV
DNA. The prevalence of HPV DNA was significantly lower
in tumour biopsies than in swabs of the tested lesion [76].
Furthermore, evidence of cutaneous HPV DNA has been
found to be both highly prevalent and persistent in the
healthy population [77]. It is possible that the results
reported here reflect a similar situation. However, there is
now some preliminary evidence from studies of molecu-
lar mechanisms, suggesting that HPV might interact with
ultra-violet radiation disturbing apoptotic pathways and
leading to cell immortalization [78]. Transforming prop-
erties of E6 and E7 proteins of some cutaneous HPV types
have also been described (reviewed in reference [71]). It
remains to be established what role, if any, HPV plays in
the pathological processes that lead to the development of
both conjunctival and cutaneous squamous cell neopla-
sia.
It should be noted that the relatively high percentage of
samples with unclassified cutaneous HPV types could rep-
resent infections with novel types of which only subge-
nomic amplicons have been sequenced [79]. However,
the other possibility is that these were infections with low
copy numbers of one of the 25 tested cutaneous HPV
types allowing only for general detection and not the
identification of specific types. With the broad spectrum
SPF10 PCR – DEIA (see Methods section) more than 50
HPV types can be detected. It cannot, therefore, be
excluded that the two cases with an indeterminate genital
HPV result actually represent a cutaneous HPV type. The
SPF10-LiPA25 system amplifies a small fragment from 65
base pairs and is therefore very suitable for the testing of
paraffin-embedded, formalin-fixed samples. Although the
conjunctiva represent mucosal tissue, the detection of
genital HPV types in 40% of the HIV seronegative cases
and in 32% of the HIV seronegative controls was unex-
pected. This finding indicates that the natural history of
HPV and their tissue tropism is not fully understood.
Conclusion
We find no evidence of an association between genital
HPV types and ocular surface squamous neoplasia. The
prevalence of cutaneous HPV was significantly higher
among cases as compared to controls. Although consist-
ent with results from two other case-control studies, the
relatively low prevalence of cutaneous HPV types among
cases (which does not differ by histological grade of
tumour) indicates that there remains considerable uncer-
tainty about a role for cutaneous HPV in the aetiology of
this tumour.
Methods
Participants
From November 1995 to May 2001 in country-wide clin-
ics, anyone with a suspect corneo-conjunctival lesion was
offered removal and histology, and enrolment in a follow-
up study with home visits. HIV serology was also offered
after pre-test counselling. Lesions were photographed and
details of the eyes and general health were recorded and
analysed in EPI INFO version 6. Those who subsequently
turned out to have lesions other than ocular surface squa-
mous neoplasia were used as a control group in the anal-
yses of HPV.
Consent and ethical approval
Information about the disease, its treatment and HIV test-
ing was given in private in vernacular by counsellors, and
consent confirmed by signature or thumbprint. The study
was approved by the Science and Ethics Committee of the
Uganda Virus Research Institute, and by the Uganda
National Council for Science and Technology.
Serology and histopathology
Venous blood was taken and screening tests for HIV anti-
bodies done, with confirmation at the Uganda Virus
Research Institute (two enzyme immunoassay tests in par-
allel, with Western blot if required). Biopsies went to St
Thomas' Hospital London for histopathology. CIN was
classified (by SBL) into 3 stages according to one, two or
three thirds thickness being dysplastic; invasive tumours
were diagnosed when the epithelial basement membrane
was breached.
HPV typing
HPV analyses were performed on DNA isolated from for-
malin-fixed, paraffin-embedded specimens. Chances of
contamination during the cutting of the sections were
minimised by discarding the initial section that was cut to
remove any environmental contamination which had
occurred while blocks were stored and by changing cryo-
stat blades in between sections. DNA was extracted from
the sections in a cabinet which had been UV-treated to
remove any contaminating DNA. Additionally, 15 nega-
tive DNA isolation controls were included. For both the
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genital HPV test and the beta HPV test, 10 Pl of a 20 ng/Pl
DNA solution per specimen was used as input for the PCR
analyses. Genital HPV genotyping was carried out using
the SPF10-LiPA25 system (SPF10 HPV LiPA, version 1; man-
ufactured by Labo Bio-Medical Products, Rijswijk, The
Netherlands) as described previously [80,81]. Briefly, the
broad spectrum SPF10 PCR amplifies a 65-base pair frag-
ment from the L1 region of the HPV genome. By using
biotinylated reverse primers the amplimers could be cap-
tured onto streptavidin-coated microtiter plates. After
denaturation of the PCR products by alkaline treatment, a
defined cocktail of digoxigenin-labeled probes was used
to detect HPV positive samples. This method that is desig-
nated the HPV DNA Enzyme Immunoassay (DEIA) pro-
vides an optical density value and is able to detect more
than 50 HPV types [82]. Amplimers from positive samples
were used for subsequent genotyping of twenty-five indi-
vidual genital HPV genotypes (high-risk HPV: 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 70, and low-risk
HPV: 6, 11, 34, 40, 42–44, 53, 54, 74) simultaneously in
a reverse hybridisation assay (RHA). Beta HPV genotyping
was performed with the PM-PCR RHA method (The skin
(beta) HPV prototype research assay; Diassay BV, Rijswijk,
The Netherlands) [83]. It consists of a broad spectrum
PCR specific for the amplification of the betaPV genus and
targets a fragment of 117 bp from the E1 region of the
HPV genome. Combined with the RHA, it was possible to
identify 25 beta HPV types (i.e., HPV type 5, 8, 9, 12, 14,
15, 17, 19–25, 36–38, 47, 49, 75, 76, 80, 92, 93 and 96).
As no DEIA was developed for this assay all amplimers
were directly analysed by RHA.
Review methods
Case series and controlled studies of HPV and ocular sur-
face squamous neoplasia published up to April 2008,
were identified through a medline search [1966–2006;
search terms (exploded, all subheadings): squamous cell
carcinoma, human papillomavirus (HPV), conjunctival
cancer], supplemented by searches of references in identi-
fied papers, by hand searches of relevant journals and by
direct contact with authors. No restriction was placed on
language of publication. No attempt was made to identify
unpublished studies or to obtain unpublished data from
published studies. There were no prospective studies. The
odds ratios used here are either those presented in the
paper or, where none were provided, they were estimated
for each study by the authors, using published figures.
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